Delivery Order SPE2DB22D3501-SPE2DB26FTF59
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,673.08 to AmerisourceBergen Drug Corp for the supply of Hemlibra 105 mg/0.7 mL vials. This firm fixed-price, non-set-aside contract was executed on May 30, 2025, with an ultimate completion date of June 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Hemlibra is a bispecific monoclonal antibody used in the treatment of hemophilia A and B, representing a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of HEMLIBRA 105 mg/0.7 mL vials totaling $6,168.26. This is a firm fixed-price delivery order with no set-aside designation, demonstrating competitive award authority. The order is scheduled for completion by August 29, 2025, with performance taking place at AmerisourceBergen's corporate facility in Conshohocken, Pennsylvania. HEMLIBRA is a specialty pharmaceutical product...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,673.08 to AmerisourceBergen Drug Corp for the supply of HEMLIBRA 105 mg/0.7 ml vials. This is a firm fixed-price, non-set-aside contract with a completion date of August 8, 2025, and was awarded on July 18, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order operates under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $35,268.76 firm fixed price delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of HEMLIBRA 150 mg/ml vials. This non-competitive delivery order, with an ultimate completion date of June 3, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 master pharmaceutical supply vehicle running through December 2026. The performance...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $34,564.08 firm fixed-price delivery order is for the supply of HEMLIBRA 150 MG/ML VIALML, a critical medical product, with a period of performance through January 22, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,336.54 firm fixed-price delivery order contract is for the supply of HEMLIBRA 105 MG/0.7 ML VIAL 0.7ML, a specialty medication. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a $23,330.40 firm fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division to provide 4,565,282 units of the specialty pharmaceutical product Hemlibra (105 mg/0.7 ml vial). The contract has an ultimate completion date of August 19, 2024 and does not have a set-aside designation. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,615.66 firm fixed-price delivery order is for the supply of HEMLIBRA 60 MG/0.4 ML VIAL 0.4ML, a specialty medication, with a completion date of November 29, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is valued at $6,168.26 and has a completion date of February 24, 2025. It is for the delivery of HEMLIBRA 105 MG/0.7 ML VIAL 0.7ML, a specialty pharmaceutical product. The contract is a firm fixed-price delivery order, with no set-aside designation indicated. AmerisourceBergen holds a larger...
- This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $26,451.57, is for the delivery of HEMLIBRA 150 MG/ML VIAL and is a Firm Fixed Price Delivery Order. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB26FTF59Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Hemlibra 105 mg/0.7 mL vials with a ceiling value of $24,673.08 under a firm fixed-price contract structure. This delivery order, which is scheduled for completion by November 17, 2025, represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. The award is executed as a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through its extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies. The Hemlibra delivery represents the company's continued role in supporting military healthcare programs worldwide by supplying specialty pharmaceuticals across multiple therapeutic domains. As a competitively awarded vendor with demonstrated capability in federal procurement, AmerisourceBergen Drug Corp maintains a significant position within DLA's pharmaceutical supply chain and is positioned as a potential awardee for the upcoming Pharmaceutical Prime Vendor Global Program Generation V contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.7k | 10/24/25 |